Noradrenaline and 5-hydroxytryptamine Modulation of Brain Dopamine Function: Implications for the Treatment of Parkinson's Disease

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1983 Jan 1

PMID 6337612

Citations 13

Authors

P Jenner

M Sheehy

C D Marsden

Affiliations

Soon will be listed here.

Abstract

1 Dopamine deficiency in the brain is the prime biochemical deficit in Parkinson's disease, but loss of noradrenaline and 5HT also may contribute. 2 In rats, 5HT-containing neurones originating from the dorsal and median raphe nuclei innervate forebrain dopamine-containing areas so as to impose an inhibitory regulatory tone on dopamine function. However, this interaction between brain dopamine and 5HT-containing neuronal systems is complex, and the effect produced appears dependent on the relative activity of each system. 3 Anatomical evidence for innervation of dopamine-containing brain regions by noradrenaline fibres in the rat is scanty, but functional studies suggest the existence of inputs which facilitate dopamine function. 4 Drug therapy designed to increase or decrease brain 5HT function has had no consistent effect in Parkinson's disease. 5 Manipulation of brain noradrenergic activity in Parkinson's disease had little effect, although the noradrenaline precursor L-threo-DOPS may reduce freezing attacks. 6 Until more specific drug molecules are available the role of brain noradrenergic and 5HT mechanisms in Parkinson's disease remains uncertain.

Citing Articles

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.

Zhou C, Guo T, Wu J, Wang L, Bai X, Gao T J Parkinsons Dis. 2021; 11(4):1631-1640.

PMID: 34366373 PMC: 8609680. DOI: 10.3233/JPD-212720.

Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson's Disease.

Sancandi M, Schul E, Economides G, Constanti A, Mercer A Front Cell Neurosci. 2019; 12:479.

PMID: 30618629 PMC: 6296349. DOI: 10.3389/fncel.2018.00479.

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications.

Miguelez C, Benazzouz A, Ugedo L, De Deurwaerdere P Front Cell Neurosci. 2017; 11:274.

PMID: 28955204 PMC: 5600927. DOI: 10.3389/fncel.2017.00274.

Unravelling the Link Between Prenatal Stress, Dopamine and Substance Use Disorder.

Pastor V, Antonelli M, Pallares M Neurotox Res. 2016; 31(1):169-186.

PMID: 27778246 DOI: 10.1007/s12640-016-9674-9.

Parkinson's disease managing reversible neurodegeneration.

Hinz M, Stein A, Cole T, McDougall B, Westaway M Neuropsychiatr Dis Treat. 2016; 12:763-75.

PMID: 27103805 PMC: 4827589. DOI: 10.2147/NDT.S98367.

References

Palkovits M, Brownstein M, Saavedra J . Serotonin content of the brain stem nuclei in the rat. Brain Res. 1974; 80(2):237-49. DOI: 10.1016/0006-8993(74)90688-x. View

Coppen A, Metcalfe M, Carroll J, Morris J . Levodopa and L-tryptophan therapy in Parkinsonism. Lancet. 1972; 1(7752):654-8. DOI: 10.1016/s0140-6736(72)90461-8. View

Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M . The raphe nuclei of the cat brain stem: a topographical atlas of their efferent projections as revealed by autoradiography. Brain Res. 1976; 113(3):449-86. DOI: 10.1016/0006-8993(76)90050-0. View

Donaldson I, DOLPHIN A, Jenner P, Marsden C, Pycock C . The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. Brain. 1976; 99(3):427-46. DOI: 10.1093/brain/99.3.427. View

Riederer P . L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutr Metab. 1980; 24(6):417-23. DOI: 10.1159/000176359. View

Waldmeier P . Serotonin--dopamine interactions in the nigrostriatal system. Eur J Pharmacol. 1979; 55(4):363-73. DOI: 10.1016/0014-2999(79)90110-9. View

Rotrosen J, Angrist B, WALLACH M, Gershon S . Absence of serotonergic influence on apomorphine-induced stereotypy. Eur J Pharmacol. 1972; 20(1):133-5. DOI: 10.1016/0014-2999(72)90230-0. View

York D . Possible dopaminergic pathway from substantia nigra to putamen. Brain Res. 1970; 20(2):233-49. DOI: 10.1016/0006-8993(70)90291-x. View

Ungerstedt U . Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl. 1971; 367:1-48. DOI: 10.1111/j.1365-201x.1971.tb10998.x. View

10.

DOLPHIN A, Jenner P, Marsden C . Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacol Biochem Behav. 1976; 5(4):431-9. DOI: 10.1016/0091-3057(76)90107-6. View

11.

Milson J, Pycock C . Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. Br J Pharmacol. 1976; 56(1):77-85. PMC: 1666754. DOI: 10.1111/j.1476-5381.1976.tb06961.x. View

12.

Fahn S, Libsch L, Cutler R . Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci. 1971; 14(4):427-55. DOI: 10.1016/0022-510x(71)90178-x. View

13.

Carter C, Pycock C . The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour. Neuropharmacology. 1981; 20(3):261-5. DOI: 10.1016/0028-3908(81)90131-3. View

14.

Dray A, Davies J, Oakley N, Tongroach P, Vellucci S . The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res. 1978; 151(3):431-42. DOI: 10.1016/0006-8993(78)91077-6. View

15.

Rinne U, SONNINEN V . Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch Neurol. 1973; 28(2):107-10. DOI: 10.1001/archneur.1973.00490200055007. View

16.

Miller J, Richardson T, Fibiger H, McLennan H . Anatomical and electrophysiological identification of a projection from the mesencephalic raphe to the caudate-putamen in the rat. Brain Res. 1975; 97(1):133-6. DOI: 10.1016/0006-8993(75)90920-8. View

17.

Baldessarini R, Amatruda 3rd T, Griffith F, Gerson S . Differential effects of serotonin on turning and sterotypy induced by apomorphine. Brain Res. 1975; 93(1):158-63. DOI: 10.1016/0006-8993(75)90295-4. View

18.

SWEET R, McDowell F, Feigenson J, LORANGER A, GOODELL H . Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology. 1976; 26(4):305-10. DOI: 10.1212/wnl.26.4.305. View

19.

Marsden C, Duvoisin R, Jenner P, Parkes J, Pycock C, Tarsy D . Relationship between animal models and clinical parkinsonism. Adv Neurol. 1975; 9:165-75. View

20.

Tarsy D, Parkes J, Marsden C . Clonidine in Parkinson disease. Arch Neurol. 1975; 32(2):134-6. DOI: 10.1001/archneur.1975.00490440084016. View